18 research outputs found

    EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH)

    Get PDF
    Physical activity (PA) may be therapeutic for people with severe mental illness (SMI) who generally have low PA and experience numerous life style-related medical complications. We conducted a meta-review of interventions and their impact on health outcomes for people with SMI, including schizophrenia-spectrum disorders, major depressive disorder (MDD) and bipolar disorder. We searched major electronic databases until January 2018 for systematic reviews with/without meta-analysis that investigated PA for any SMI. We rated the quality of studies with the AMSTAR tool, grading the quality of evidence, and identifying gaps, future research needs and clinical practice recommendations. For MDD, consistent evidence indicated that PA can improve depressive symptoms versus control conditions, with effects comparable to those of antidepressants and psychotherapy. PA can also improve cardiorespiratory fitness and quality of life in people with MDD, although the impact on physical health outcomes was limited. There were no differences in adverse events versus control conditions. For MDD, larger effect sizes were seen when PA was delivered at moderate-vigorous intensity and supervised by an exercise specialist. For schizophrenia-spectrum disorders, evidence indicates that aerobic PA can reduce psychiatric symptoms, improves cognition and various subdomains, cardiorespiratory fitness, whilst evidence for the impact on anthropometric measures was inconsistent. There was a paucity of studies investigating PA in bipolar disorder, precluding any definitive recommendations. No cost effectiveness analyses in any SMI condition were identified. We make multiple recommendations to fill existing research gaps and increase the use of PA in routine clinical care aimed at improving psychiatric and medical outcomes

    Descriptive characteristics of study participants.

    No full text
    <p>A total sample size of N = 50 was included in the analysis. Descriptive data are presented in means (M) and standard deviations (SD). Absolute numbers of participants are given (N) and expressed as percentage (%).</p><p><b>Abbreviations:</b> means (<i>M</i>); standard deviation (<i>SD</i>), brain-derived neurotrophic factor (BDNF); Insomnia Severity Index (ISI); Perceived Stress Scale (PSS); restless legs syndrome (RLS), periodic limb movement (PLM).</p

    Correlation between serum BDNF levels and scores on the <i>Perceived Stress Scale</i> (PSS) by insomnia severity groups according to the <i>Insomnia Severity Index</i> (ISI).

    No full text
    <p>Analyses showed a significant correlation (partial correlation controlled for smoking) between BDNF and stress only in subjects with no insomnia (<i>r<sub>p</sub></i> = −0.511, p = 0.013) compared to subjects with sub threshold (<i>r<sub>p</sub></i> = 0.069, <i>p</i> = 0.814) or clinical insomnia (<i>r<sub>p</sub></i> = 0.199, <i>p</i> = 0.608). White squares represent subjects with no insomnia, black circles represent subjects with sub threshold and black triangles represent subjects with clinical insomnia. (Inset) Mean serum BDNF levels of the insomnia severity groups. Plotted means and standard errors estimated by ANCOVA with serum BDNF as dependent variable, insomnia severity group as independent variable and smoking as covariate. For all three insomnia severity groups the overall effect on serum BDNF was not significant (<i>F</i>(2) = 2.67; <i>p</i> = 0.080). Contrasts showed that serum BDNF levels in the group with no insomnia were significantly higher compared to the groups reporting sub threshold and clinical insomnia (<i>F</i>(1) = 5.33; <i>p</i> = 0.026); (no insomnia n = 24; sub threshold insomnia n = 16, clinical insomnia n = 10). * Denotes statistical significance at <i>p</i><0.05</p

    Stress experience in subjects suffering from current insomnia.

    No full text
    <p>Correlation between insomnia severity score (indicated by the <i>Insomnia Severity Index</i> (ISI)) and stress perception (indicated by the <i>Perceived Stress Scale</i> (PSS)). Analysis showed a significant correlation between scores on the ISI and the PSS across the whole sample (<i>r<sub>p</sub></i> = 0.548, <i>p</i><0.001). * Denotes statistical significance at <i>p</i><0.05.</p

    Additional file 1: of Validation of the German version of the insomnia severity index in adolescents, young adults and adult workers: results from three cross-sectional studies

    No full text
    Validation of the German Version of the Insomnia Severity Index_Supplementary Online Material. Insomnia Severity Index – Deutsche Übersetzung (German translation). This file provides the German translation of the Insomnia Severity Index, as well as a guide for (a) calculating an overall index and (b) interpreting the overall score. (DOCX 81 kb

    Correlation of salivary cortisol, baseline characteristics, glucose and lipid metabolism as well as catecholamines; filled circles represent controls, filled triangles represent insomniacs; p values including all participants are presented.

    No full text
    <p>Correlation of salivary cortisol, baseline characteristics, glucose and lipid metabolism as well as catecholamines; filled circles represent controls, filled triangles represent insomniacs; p values including all participants are presented.</p

    Midnight and morning salivary cortisol concentrations in insomniacs and controls.

    No full text
    <p>Midnight values were significantly higher in insomniacs than in controls (p = 0.02), whereas morning values did not differ significantly (p = 0.18).</p
    corecore